Zum Inhalt springen

Gene therapy is halting cancer

A type of gene therapy called CAR-T that has extended survival for thousands of patients with leukemia and other blood cancers is being adapted at UC San Francisco to treat people with glioblastoma, the most common and deadly adult brain tumor. This new more powerful version of CAR-T employs a novel technology developed at UCSF called synthetic notch (synNotch) that both protects healthy tissue from damage and enables the treatment to work more effectively.  UCSF opened enrollment this week for a clinical trial that is using the technology for the first time in people. A second trial, also at UCSF, is slated for 2025.  Approximately 12,000 Americans are diagnosed each year with glioblastoma. Patients survive on average for just 15 months after their diagnosis, and new treatments are urgently needed.  “This project is a prime example of bench-to-bed translation within… 

more »Gene therapy is halting cancer

BiomX Announces the Appointment of Susan Blum to its Board of Directors

CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. BiomX Announces the Appointment of Susan Blum to its Board of Directors

Korro Announces $70 Million Private Placement

CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) — Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that it has entered into a subscription agreement with certain new and existing accredited investors to issue and sell an aggregate of 1,249,283 shares of its common stock in a private placement (PIPE) that is expected to result in gross proceeds of approximately $70.0 million, before deducting placement agent fees and estimated offering expenses. The PIPE is expected to close on April 22, 2024, subject to the satisfaction of customary closing conditions. Korro Announces $70 Million Private Placement

NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit

SANTA ANA, Calif., April 18, 2024 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details around its NK cell therapy in neurodegenerative disease, review its preclinical data in Parkinson’s disease, and highlight clinical safety and efficacy data from the Company’s recently completed Phase 1 clinical trial of SNK01, autologous natural killer cell therapy, in Alzheimer’s disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit to be held in Boston, MA, from April 23–25, 2024. NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development… 

more »NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit

NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit

SANTA ANA, Calif., April 18, 2024 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details around its NK cell therapy in neurodegenerative disease, review its preclinical data in Parkinson’s disease, and highlight clinical safety and efficacy data from the Company’s recently completed Phase 1 clinical trial of SNK01, autologous natural killer cell therapy, in Alzheimer’s disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit to be held in Boston, MA, from April 23–25, 2024. NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development… 

more »NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit

Addex to Present at the Swiss Biotech Day 2024

Geneva, Switzerland, April 19, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April 22 – 23, 2024 at the Congress Center in Basel, Switzerland. Addex to Present at the Swiss Biotech Day 2024

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly U.S. Food and Drug Administration (FDA) approved high-concentration interchangeable biosimilar to Humira. Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

Dr. Ulrich Paul Hinkel, PD Dr. Christian Hohenstein, Dr. Mark Williams, PD Dr. Birger Mensel, Mario Schulter und Dr. Mark-Christopher Spoerl (v. l. n. r.). /credits: Rhön-Klinikum AG

Zentralklinik Bad Berka betreut Englische Nationalelf

Die englische Fußballnationalmannschaft kooperiert während der Fußball-EM mit der Zentralklinik Bad Berka. Mannschaftsarzt Dr. Mark Williams überzeugte sich bei einem Besuch der Klinik von den diagnostischen und therapeutischen Möglichkeiten für die Spieler und das Begleit-Team. Bei der Kooperation spielt insbesondere die 24-Stunden-Verfügbarkeit modernster Diagnostik, wie z. B. MRT, CT sowie die herausragende Kompetenz der Mediziner und Pflegekräfte eine entscheidende Rolle. „Wir freuen uns über das Interesse und das Vertrauen. Auch wenn wir alle hoffen, dass die Fußball-EM verletzungs- und erkrankungsfrei abläuft. Gern sind wir als kompetente Unterstützer für die Sportler und alle anderen Teambegleiter da, obwohl alle hoffen, dass wir im Turnier der ‚Ersatzbank-Akteur‘ bleiben“, erklärt Geschäftsführer Mario Schulter. Die zum Verbund der RHÖN-KLINIKUM AG gehörende Zentralklinik Bad Berka zählt mit ihren 21 Fachkliniken und Fachabteilungen sowie ihrer über 120-jährigen Geschichte zu den großen Thüringer Kliniken. Jährlich werden hier rund… 

more »Zentralklinik Bad Berka betreut Englische Nationalelf

Mittelinfrarot-Mikroskopie besser als je zuvor

Öffnet sich aktuell womöglich ein neues Kapitel in der Betrachtung des Mikrokosmos? Forscher der Universität Tokio haben eine verbesserte Form der Mittelinfrarot-Mikroskopie entwickelt, die es ermöglicht, die Strukturen innerhalb lebender Bakterien mit einer bisher unerreichten Klarheit zu sehen. Forscher zeigen sich überrascht Die neue Methode, die in der Fachzeitschrift Nature Photonics veröffentlicht wurde, erreicht eine […] Neue Dimensionen der Sichtbarkeit: Mittelinfrarot-Mikroskopie besser als je zuvor

Huawei stellt KI-Technologien vor

Shenzhen, China (ots/PRNewswire) – Auf dem Huawei Analyst Summit 2024 hielt Steven Zhao, Vice President der Produktlinie Datenkommunikation bei Huawei, einen Vortrag mit dem Titel ?Accelerating Network Transformation Towards All Intelligence“ (Beschleunigung der Netzwerktransformation für die allgegenwärtige Intelligenz). Herr Zhao beleuchtete, wie Huawei KI-Technologien eingeführt hat, um die Netzwerkfunktionen auf Fall-, Prozess- und Systemebene zu […] Huawei stellt KI-Technologien vor, um die Transformation von Netzwerken für die allgegenwärtige Intelligenz im Net5.5G-Zeitalter zu beschleunigen